Immunic (IMUX)
(Delayed Data from NSDQ)
$1.27 USD
+0.03 (2.42%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $1.26 -0.01 (-0.79%) 6:08 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Brokerage Reports
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 41 - 60 ( 213 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q2: No Steroid Interaction Readthrough From UC to MS Trials; Pipeline Updates
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Ulcerative Colitis Data Murky, Focus Shifts to Additional 2022 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
CALDOSE-1 Does Not Meet Primary Endpoint; Multiple Shots on Goal with Pipeline
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Update - Still Tracking Towards a Catalyst-Rich Year
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q1: On Track to Report Topline Induction-Phase Data from Ph2 CALDOSE-1 in June
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Highlights from UC KOL Call: UnCovering the Potential for IMU-838 in UC
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Panels & Fireside Chats at Our 34th Annual ROTH Conference
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Update - 2022 Certainly Looks Like It Will Be a Big Year for Immunic
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY21: Looking Ahead to Multiple Key Data Readouts in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-935 Patent Application Allowed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Positive IMU-935 Phase 1 Data; Prostate Cancer Trial Started; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R